Oxford Sciences Enterprises

OSE sources exclusively from the University of Oxford, the Harwell Campus, and Culham Science Centre. Its partnership with the university gives it privileged access to academic research before it reaches the wider market. The firm works hand-in-hand with researchers and innovators to explore commercial potential and co-create ventures, rather than waiting for fully formed spinouts to raise institutional rounds.

No. OSE is an independent investment company, owned by global shareholders rather than the university. It was founded in 2015 through a structured partnership with the University of Oxford, but its investment committee and funding decisions operate autonomously. The firm’s CEO is Ed Bussey, and its 60-person team is based in Oxford, not on the university payroll.

Yes. OSE funds companies from pre-seed through growth stages. Its venture-building model often begins before company formation, co-creating ventures with researchers and funding them through the earliest technical and commercial milestones. Landmark exits like Oxford Ionics and Dark Blue Therapeutics both started as early-stage OSE portfolio companies.

OSE invests in three primary sectors: Deep Tech, Life Sciences, and HealthTech. Deep Tech encompasses quantum computing, AI, and advanced materials; Life Sciences includes biotech and therapeutics; HealthTech covers medical devices and digital health. Confirmed positions include Oxford Ionics (quantum computing), Dark Blue Therapeutics and Alethio Therapeutics (oncology), and OMass Therapeutics (structural biology).

Yes. OSE has built a network of over 300 specialist co-investors that invest alongside the firm from pre-seed to growth. The firm’s own shareholders — global investors who have committed more than £850m — often participate as co-investors. In October 2025, OSE made its first co-investment with the Ellison Institute of Technology, a $60m Series A for Wild Bioscience.

Oxford Ionics was an OSE portfolio company from its early stages. The quantum computing spinout, founded by Dr. Chris Ballance, was acquired by IonQ in June 2025 for $1.075bn (per the firm, June 2025). OSE highlighted the deal as a case study in its venture-building model, demonstrating how patient capital and hands-on support can turn an academic breakthrough into a billion-dollar exit.

OSE makes direct investments into its portfolio companies and co-invests alongside external investors. It does not publicly describe itself as managing a fund-of-funds. Its structure is closer to a single-GP venture capital firm combined with a company-creation studio, where funding is allocated directly to ventures rather than through third-party fund commitments.